top of page

Mineralys CEO John Congleton describes the rational of targeting aldosterone for hypertension and discusses his company's pivotal data

  • Sep 8, 2025
  • 1 min read

He describes the science behind aldosterone and Mineralys' program lorundrostat. The company had pivotal data earlier this year and plans to have a pre-NDA meeting with FDA in the fourth quarter.




Coverage brought to you by:


Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

HSBC_IB_Stacked_logo.png

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

bottom of page